XPON vs CVKD Comparison

Expion360 Inc focuses on the design, assembly, manufacturing, and sale of lithium iron phosphate (LiFePO4) batteries and related accessories for RV, marine, and industrial applications. Its high-performance battery solutions are designed for high energy density and a compact footprint, supported by engineering and intellectual property to enhance safety, quality, and performance. The company also engages in product design, development, and collaboration to strengthen customer relationships. It serves dealers, wholesalers, private-label customers, and OEMs, who distribute its products to end consumers. Its segment is Energy Storage (ES), providing lithium-based energy solutions backed by durable materials, optimized internal structures, and responsive customer service.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.